Clinical Efficacy and Safety of Tender Point Infiltration (TPI) for Acute and Subacute Zoster Associated Pain
Launched by BEIJING TIANTAN HOSPITAL · Mar 27, 2024
Trial Information
Current as of July 23, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a treatment method called Tender Point Infiltration (TPI) to help relieve severe pain caused by a skin infection known as herpes zoster (commonly called shingles). The researchers want to find out if adding TPI, which involves injecting a local anesthetic and steroids into painful areas, can improve pain relief for patients compared to just using antiviral medications. Participants in the trial will be adults aged 18 to 75 who have had a shingles rash for less than 90 days and are experiencing significant pain.
To be eligible for this trial, patients must have a pain level above a certain threshold and agree to participate. Those with infections at the injection site, severe health issues, a history of drug abuse, or who are pregnant or breastfeeding are not eligible. If you join the study, you can expect to receive either the TPI treatment or standard antiviral therapy, and you will be monitored to see how well the treatment works for your pain. This trial is currently recruiting participants and aims to provide better options for managing shingles-related pain.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Patients with onset of HZ rash less than 90 days.
- • 2. HZ affected the spinal nerves (cervical/thoracic/lumbar nerve).
- • 3. Aged 18 to 75 years (inclusive).
- • 4. Pain intensity \> 7 cm on a visual analogue scale (VAS 0-10 cm).
- • 5. Agreed to sign the informed consent form.
- Exclusion Criteria:
- • 1. Infection at the puncture site.
- • 2. Poor general situation unable to be treated.
- • 3. A history of abuse of narcotics.
- • 4. Non-compliance or inability to complete the self-evaluation questionnaires.
- • 5. Pregnancy or lactation.
About Beijing Tiantan Hospital
Beijing Tiantan Hospital, affiliated with Capital Medical University, is a leading medical institution in China renowned for its expertise in neurology, neurosurgery, and various other specialties. As a prominent clinical trial sponsor, the hospital is committed to advancing medical research and improving patient outcomes through innovative studies. With a focus on high-quality clinical trials, Beijing Tiantan Hospital adheres to rigorous ethical standards and regulatory requirements, fostering collaboration with academic institutions and industry partners to facilitate the development of cutting-edge therapies and interventions. Its state-of-the-art facilities and experienced research team enable the hospital to play a pivotal role in the global medical research landscape.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Beijing, Beijing, China
Patients applied
Trial Officials
Fang Luo, M.D.
Study Director
Beijing Tiantan Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported